ANAB - AnaptyBio Inc

-

$undefined

N/A

(N/A)

AnaptyBio Inc NasdaqGS:ANAB AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Location: 10770 Wateridge Circle, San Diego, CA, 92121-5801, United States | Website: https://www.anaptysbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

659.1M

Cash

339.9M

Avg Qtr Burn

-27.2M

Short % of Float

50.03%

Insider Ownership

5.06%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
JEMPERLI (Dostarlimab-gxly) Details
Solid tumor/s, Cancer, Endometrial cancer

Approved

Quarterly sales

Phase 3

Data readout

Dostarlimab+ belrestotug Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Dostarlimab Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Imsidolimab (ANB019) (anti-IL-36R) Details
Hidradenitis suppurativa, Generalized pustular psoriasis, EGFRi-mediated skin toxicity, Ichthyosis, Palmoplantar pustulosis, Acne

Phase 3

Update

Rosnilimab (ANB030) Details
Rheumatoid arthritis, Autoimmune disease

Susp. Mover™

Phase 2b

Data readout

Phase 2

Data readout

Phase 1b

Update

Phase 1

Initiation

Failed

Discontinued

Rosnilimab (ANB030) (PD-1 agonist) Details
Alopecia areata, Vitiligo, Skin disease/disorder

Failed

Discontinued

Etokimab (ANB020) Anti-IL-33 Details
Chronic Rhinosinusitis with Nasal Polyps

Failed

Discontinued